Comparison of Bypassing Agents in Bleeding Reduction in Treatment of Bleeding Episodes in Patients With Haemophilia and Inhibitors

CONTEXT: Mild-to-moderate bleeding disorders in haemophilia are primarily treated via recombinant activated factor VII a (rFVIIa) or activated prothrombin complex concentrate (aPCC). However, the efficacy of each bypassing agents may vary and none of them is universally effective. EVIDENCE ACQUISITI...

Descripción completa

Detalles Bibliográficos
Autores principales: Golestani, Mina, Eshghi, Peyman, Rasekh, Hamid Reza, Cheraghali, Abdol Majid, Salamzadeh, Jamshid, Imani, Ali
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Kowsar 2014
Materias:
Review Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4341353/
https://www.ncbi.nlm.nih.gov/pubmed/25763245
http://dx.doi.org/10.5812/ircmj.24551

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4341353/
https://www.ncbi.nlm.nih.gov/pubmed/25763245
http://dx.doi.org/10.5812/ircmj.24551

Ejemplares similares